Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Colorectal Neoplasms 7 Carcinoma, Renal Cell 7 Neoplasms 6 Lymphoma, Non-Hodgkin 6 Carcinoma, Non-Small-Cell Lung 6 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Pancreatic Neoplasms 4 Ovarian Neoplasms 4 Lymphoma 4 Leukemia, Lymphocytic, Chronic, B-Cell 4 Carcinoma, Merkel Cell 4 Triple Negative Breast Neoplasms 3 Stomach Neoplasms 3 Squamous Cell Carcinoma of Head and Neck 3 Recurrence 3 Neoplasm Metastasis 3 Multiple Myeloma 3 Head and Neck Neoplasms 3 Carcinoma, Transitional Cell 3 Small Cell Lung Carcinoma 2 Skin Neoplasms 2 Lymphoma, Follicular 2 Lymphoma, B-Cell 2 Lung Neoplasms 2 Leukemia, Myeloid, Acute 2 Hematologic Neoplasms 2 Esophageal Neoplasms 2 Endometrial Neoplasms 2

Interventions

fludarabine 1 aldesleukin 1 Interleukin-2 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Ovarian Cancer Metastatic × Interleukin-2 × Clear all

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn

Ovarian Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡